Screener
Iovance Biotherapeutics, Inc. IOVA Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Iovance Biotherapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
FAQ
- What is Iovance Biotherapeutics, Inc.'s debt-to-equity?
- Iovance Biotherapeutics, Inc. (IOVA) reported debt-to-equity of 0.1× in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s debt-to-equity changed year-over-year?
- Iovance Biotherapeutics, Inc.'s debt-to-equity decreased by 16.3% year-over-year, from 0.1× to 0.1×.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s debt-to-equity?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s debt-to-equity has grown at a -2.5% compound annual growth rate (CAGR), from 0.1× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Iovance Biotherapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude